Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : ASK Vendit Off Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: DOUG H who wrote (14361)	10/2/2000 12:42:57 AM
From: Boplicity	Read Replies (1) \| Respond to of 19374

SQNM has bottomed. askresearch.com take note of the recent increase in vol. to the upside and the lack of vol to the downside as the stock begins it's rebound after a 7 month base. Also note the 20 day passes through the 50 day line and the fact the stock was up 4 points Friday which was a down day on good news. Plus, the base has an upward bias to it. Greg biz.yahoo.com <<SAN DIEGO, Sept. 29 /PRNewswire/ -- SEQUENOM(TM), Inc. (Nasdaq: SQNM), the leading provider of single nucleotide polymorphism (SNP) analysis strategies and technology, today announced that it has sold four additional MassARRAY systems, raising SEQUENOM's installed commercial base of systems to 16. Hitachi, Ltd. (NYSE: HIT), a leading global electronics company, has purchased a MassARRAY system following the company's recent expansion into the life science arena. Hitachi's Life Science Group has chosen the MassARRAY system for its internal SNP marker validation projects while providing genotyping services to the Japanese SNP analysis market. Hitachi established the Life Science Group last year to promote the growth of biotechnology businesses in Japan and to improve the health and prosperity of people around the world. Genetics Institute, a unit of Wyeth-Ayerst and a wholly owned subsidiary of American Home Products Corporation (NYSE: AHP), has purchased a MassARRAY system for the high throughput quality control of oligonucleotides, short strands of synthetic DNA used in various genomics research programs at Genetics Institute and Wyeth-Ayerst. SEQUENOM's MassARRAY system is the recognized gold standard for oligonucleotide quality control. Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC), a leader in applying population genomics and informatics to the development of personalized medicines, has purchased a second MassARRAY system for high-throughput SNP analysis. The additional system purchase follows a previously announced agreement between the two companies establishing SEQUENOM's MassARRAY system as the exclusive platform for Genaissance's HAP Typing(TM) facility. The facility was designed for the high-throughput analysis of samples from clinical trials. Integrated DNA Technologies, Inc. (IDT), a leader in high volume oligonucleotide production, has also purchased a second MassARRAY system from SEQUENOM. IDT has integrated the MassARRAY technology into its high throughput oligonucleotide synthesis platform to support its automated production and quality control. The previously announced agreement secures a dedicated and reliable supply of oligonucleotides, a critical factor in assay development and utilization of genotyping technologies, for SEQUENOM and its customers. "Hitachi, Genetics Institute, Genaissance and IDT represent four distinct segments in genomics and we are pleased that they have each chosen our MassARRAY system," said Toni Schuh, Ph.D., SEQUENOM's President and CEO. "In particular, we are pleased with the opportunity to participate in the emerging Asian biotechnology market through our relationship with Hitachi. This marks our entry into a market with largely untapped growth potential and symbolizes the widespread demand for our technology. "SEQUENOM's technology and integrated approach to SNP analysis enable full genome scans, which gives us a leadership position in the field," continued Dr. Schuh. "Our unique competitive advantages include automated high-throughput assay design, the ability to determine allele frequencies, the availability of an in-house reference DNA bank and ultimate data quality. SEQUENOM's customers buy more than just genotyping technology; they buy a relationship with our company. Our increasing number of customers demonstrates confidence in this approach and supports our leadership position." >> Warning stock reports the Oct 26th and is a recent IPO. I see this stocks as a trade to 49 area, if it breaks out there I will add. First resistance is 60 area. If I still hold it near the earnings date I might be a seller a day or two before. Greg